BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19738092)

  • 1. Genetic modifiers of liver disease in cystic fibrosis.
    Bartlett JR; Friedman KJ; Ling SC; Pace RG; Bell SC; Bourke B; Castaldo G; Castellani C; Cipolli M; Colombo C; Colombo JL; Debray D; Fernandez A; Lacaille F; Macek M; Rowland M; Salvatore F; Taylor CJ; Wainwright C; Wilschanski M; Zemková D; Hannah WB; Phillips MJ; Corey M; Zielenski J; Dorfman R; Wang Y; Zou F; Silverman LM; Drumm ML; Wright FA; Lange EM; Durie PR; Knowles MR;
    JAMA; 2009 Sep; 302(10):1076-83. PubMed ID: 19738092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SERPINA1 Z allele is associated with cystic fibrosis liver disease.
    Boëlle PY; Debray D; Guillot L; Corvol H;
    Genet Med; 2019 Sep; 21(9):2151-2155. PubMed ID: 30739910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystic fibrosis-associated liver disease in children.
    Wasuwanich P; Karnsakul W
    Minerva Pediatr; 2020 Oct; 72(5):440-447. PubMed ID: 32418413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural history of cystic fibrosis liver disease a prospective cohort study.
    Rowland M; Drummond J; Connolly L; Daly E; McCormick PA; Bourke B; ;
    J Cyst Fibros; 2023 Nov; 22(6):1054-1061. PubMed ID: 37495468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population.
    Polineni D; Piccorelli AV; Hannah WB; Dalrymple SN; Pace RG; Durie PR; Ling SC; Knowles MR; Stonebraker JR
    PLoS One; 2018; 13(10):e0205257. PubMed ID: 30307979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modifier genes in cystic fibrosis-related liver disease.
    Debray D; Corvol H; Housset C
    Curr Opin Gastroenterol; 2019 Mar; 35(2):88-92. PubMed ID: 30585791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and genetic risk factors for cystic fibrosis-related liver disease in Egyptian CF children: A single-center experience.
    El-Faramawy A; Nasr SZ; Emam MMSA; Fahmy HMH
    Pediatr Pulmonol; 2024 Feb; 59(2):465-471. PubMed ID: 38038166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis.
    Bader RM; Jonas MM; Mitchell PD; Wiggins S; Lee CK
    J Cyst Fibros; 2019 Mar; 18(2):280-285. PubMed ID: 30509601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease.
    Leung DH; Khan M; Minard CG; Guffey D; Ramm LE; Clouston AD; Miller G; Lewindon PJ; Shepherd RW; Ramm GA
    Hepatology; 2015 Nov; 62(5):1576-83. PubMed ID: 26223427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variation in severe cystic fibrosis liver disease is associated with novel mechanisms for disease pathogenesis.
    Stonebraker JR; Pace RG; Gallins PJ; Dang H; Aksit MA; Faino AV; Gordon WW; MacParland S; Bamshad MJ; Gibson RL; Cutting GR; Durie PR; Wright FA; Zhou YH; Blackman SM; O'Neal WK; Ling SC; Knowles MR
    Hepatology; 2024 Mar; ():. PubMed ID: 38536042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced but not mild liver disease is a predictor of decreased survival in children with cystic fibrosis, with far greater impact in females: A 27-year real-life cohort study.
    Baldissera M; Lewindon PJ; Ramm LE; Hartel GF; Mattiello R; Ramm GA
    J Cyst Fibros; 2022 Mar; 21(2):230-235. PubMed ID: 34949555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and characteristics of cystic fibrosis liver disease: a study highlighting the lack of histological diagnosis.
    Issa Z; Gohy S; Zech F; Baldin P; Delire B; Dahlqvist G
    Clin Res Hepatol Gastroenterol; 2022 Nov; 46(9):101977. PubMed ID: 35772685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis-related liver disease is an independent risk factor for mortality and increased health care resource utilization in hospitalized pediatric patients with cystic fibrosis.
    Thavamani A; Umapathi KK; Kutney K; Sferra TJ; Sankararaman S
    Pediatr Pulmonol; 2022 Jul; 57(7):1717-1725. PubMed ID: 35499220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the mutation of the SERPINA1 gene contribute to liver damage and cholestasis in patients with diagnosed cystic fibrosis? preliminary study.
    Więcek S; Woś H; Kordys-Darmolińska B; Sankiewicz-Szkółka M; Grzybowska-Chlebowczyk U
    Dev Period Med; 2015; 19(1):92-7. PubMed ID: 26003074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma-glutamyl transpeptidase-to-platelet ratio as a biomarker of liver disease and hepatic fibrosis severity in paediatric Cystic Fibrosis.
    Calvopina DA; Lewindon PJ; Ramm LE; Noble C; Hartel GF; Leung DH; Ramm GA
    J Cyst Fibros; 2022 Mar; 21(2):236-242. PubMed ID: 34953741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis.
    Stonebraker JR; Ooi CY; Pace RG; Corvol H; Knowles MR; Durie PR; Ling SC
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1207-1215.e3. PubMed ID: 27062904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor necrosis factor α (-308 A/G) polymorphism is associated with cystic fibrosis in Mexican patients.
    Sanchez-Dominguez CN; Reyes-Lopez MA; Bustamante A; Cerda-Flores RM; Villalobos-Torres Mdel C; Gallardo-Blanco HL; Rojas-Martinez A; Martinez-Rodriguez HG; Barrera-Saldaña HA; Ortiz-Lopez R
    PLoS One; 2014; 9(3):e90945. PubMed ID: 24603877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of MBL2, TGF-beta1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis.
    Faria EJ; Faria IC; Ribeiro JD; Ribeiro AF; Hessel G; Bertuzzo CS
    J Bras Pneumol; 2009 Apr; 35(4):334-42. PubMed ID: 19466271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease.
    Freeman AJ; Sellers ZM; Mazariegos G; Kelly A; Saiman L; Mallory G; Ling SC; Narkewicz MR; Leung DH
    Liver Transpl; 2019 Apr; 25(4):640-657. PubMed ID: 30697907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic Manifestations of Cystic Fibrosis.
    Sakiani S; Kleiner DE; Heller T; Koh C
    Clin Liver Dis; 2019 May; 23(2):263-277. PubMed ID: 30947876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.